Trial Profile
Cisplatin or ImmunoTHerapy in Association With Definitive Radiotherapy in HPV-related oropharyngEal Squamous Cell Carcinoma: a Randomized Phase II Trial.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Feb 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Cisplatin
- Indications Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms CITHARE
- 16 Feb 2023 Status changed from active, no longer recruiting to completed.
- 27 Apr 2022 Planned End Date changed from 1 Mar 2022 to 1 Mar 2023.
- 02 Aug 2021 Planned End Date changed from 1 Mar 2023 to 1 Mar 2022.